squirrelcone
Lv4
500 积分
2023-05-04 加入
-
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
1天前
待确认
-
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis
4天前
已完结
-
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
8天前
已完结
-
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
9天前
已完结
-
Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis
9天前
已完结
-
Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma
18天前
已完结
-
CAR T-cell therapy for multiple myeloma: state of the art and prospects
18天前
已完结
-
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis
23天前
已完结
-
Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data
23天前
已完结
-
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma
23天前
已完结